Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination

Clinical Cancer Research

Volumn 23, Issue 8, 2017, Pages 1898-1909

  Batich, Kristen A ^a   Reap, Elizabeth A ^a   Archer, Gary E ^a   Sanchez Perez, Luis ^a   Nair, Smita K ^a   Schmittling, Robert J ^a   Norberg, Pam ^a   Xie, Weihua ^a   Herndon, James E ^a   Healy, Patrick ^a   McLendon, Roger E ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Bigner, Darell ^a   Vlahovic, Gordana ^a   Mitchell, Duane A ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; DACARBAZINE; IMMUNOLOGICAL ADJUVANT; MATRIX PROTEIN; PHOSPHOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INTENSIFICATION; DRUG WITHDRAWAL; FEMALE; GENE; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IDH 1 GENE; IDH 2 GENE; IMMUNOPATHOLOGY; KARNOFSKY PERFORMANCE STATUS; LONG TERM SURVIVAL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; REGULATORY T LYMPHOCYTE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; DENDRITIC CELL; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHOSPHOPROTEINS; T-LYMPHOCYTES, REGULATORY; VIRAL MATRIX PROTEINS;

EID: 85018819423     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2057     Document Type: Article

References (38)

1. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on longterm survivors with malignant astrocytomas. Ann Neurol 1990;28: 818-22.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008; 10:10-8.
4. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62:3347-50.
5. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008;359: 539-41.
6. Dziurzynski K, Chang SM,Heimberger AB, Kalejta RF, McGregorDallas SR, Smit M, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 2012;14:246-55.
7. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol 2012;86:854-64.
8. Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res 2014;20:2684-94.
9. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015;519:366-9.
10. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13: 324-33.
11. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JEII, Lally-Goss D, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009;8:2773-9.
12. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.
13. Slingluff CLJ, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
14. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298: 850-4.
15. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 2002;99:931-6.
16. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602.
17. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10:332-7.
18. Nair S, Archer GE, Tedder TF. Isolation and generation of human dendritic cells. Curr Protoc Immunol 2012; Chapter 7:Unit 7.32.
19. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
20. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
21. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009;28:484-93.
22. Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A. Guidelines for the automated evaluation of Elispot assays. Nat Protoc 2015;10: 1098-115.
23. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
24. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85: 704-10.
25. Mitchell DA, Sayour EJ, Reap E, Schmittling R, DeLeon G, Norberg P, et al. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol Res 2015;3:320-5.
26. Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, et al. Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors inmice. PLoS One 2013;8: e59082.
27. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201:723-35.
28. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H, et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 2006;176:4632-9.
29. Mehta MP, Wang M, Aldape K, Stupp R, Jaeckle KA, Blumenthal D, et al. RTOG 0525: exploratory subset analysis from a randomized phase III trial comparing standard (std) adjuvant temozolomide (TMZ) with a dosedense (dd) schedule for glioblastoma (GBM). Int J Radiat Oncol Biol Phys 2011;81:S128-9.
30. Fadul CE, Fisher JL, Gui J, Hampton TH, Côté AL, Ernstoff MS. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 2011;13:393-400.
31. Galgano A, Barinov A, Vasseur F, de Villartay JP, Rocha B. CD8 memory cells develop unique DNA repair mechanisms favoring productive division. PLoS One 2015;10:e0140849.
32. Fecci PE, Mitchell DA, Whitesides JF, XieW, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients withmalignant glioma. Cancer Res 2006;66:3294-302.
33. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007;13:2158-67.
34. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002;110:185-92.
35. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011;118:3003-12.
36. Prlic M, Jameson SC. Homeostatic expansion versus antigen-driven proliferation: common ends by different means? Microbes Infect 2002;4: 531-7.
37. Kieper WC, Jameson SC. Homeostatic expansion and phenotypic conversion of näive T cells in response to self peptide/MHC ligands. Proc Natl Acad Sci U S A 1999;96:13306-11.
38. Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005;65:10569-77.